# Mark E. Dudley

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/mark-e-dudley/

## Facts

| Field | Value |
| --- | --- |
| Citations | 47,005 |
| Field | CAR-T cell therapy research |
| h-index | 67 |
| i10-index | 109 |
| OpenAlex ID | https://openalex.org/A5072313658 |
| Works | 208 |

## Researcher papers

- [Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes](https://scholariq.org/papers/cancer-regression-and-autoimmunity-in-patients-after-clonal-repopulation-with/)
- [Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes](https://scholariq.org/papers/cancer-regression-in-patients-after-transfer-of-genetically-engineered/)
- [Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy](https://scholariq.org/papers/durable-complete-responses-in-heavily-pretreated-patients-with-metastatic/)
- [Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma](https://scholariq.org/papers/immunologic-and-therapeutic-evaluation-of-a-synthetic-peptide-vaccine-for-the/)
- [Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic Melanoma](https://scholariq.org/papers/adoptive-cell-transfer-therapy-following-non-myeloablative-but-lymphodepleting/)
- [Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1](https://scholariq.org/papers/tumor-regression-in-patients-with-metastatic-synovial-cell-sarcoma-and-melanoma/)
- [Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor](https://scholariq.org/papers/chemotherapy-refractory-diffuse-large-b-cell-lymphoma-and-indolent-b-cell/)
- [Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19](https://scholariq.org/papers/eradication-of-b-lineage-cells-and-regression-of-lymphoma-in-a-patient-treated/)
- [A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response](https://scholariq.org/papers/a-pilot-trial-using-lymphocytes-genetically-engineered-with-an-ny-eso-1-reactive/)

## Researcher topics

- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [Virus-based gene therapy research](https://scholariq.org/topics/virus-based-gene-therapy-research-2/)
- [Immune Cell Function and Interaction](https://scholariq.org/topics/immune-cell-function-and-interaction/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.